HispanicBusiness

LOS ANGELES, CA -- (Marketwire) -- 02/06/13 -- While trading catalyst driven small cap biotechs can be risky, if executed with discipline and closely monitored technical chart analysis, these types of trades can offer rewarding returns to investors.

Along with the rest of the market, a few of our recent catalyst trade picks have done very well.

We first wrote about Bioline RX Ltd. on January 15th of this year when the stock was trading in $2.80 range. The stock recently hit a high of $4.85 on finance.yahoo.com%2fq%2fhp%3fs%3dBLRX%2bHistorical%2bPrices">January 31st.

Another recent successful pick is EDAP TMS SA, which we first mentioned as a catalyst trade pick list on January 3rd, when shares were trading the $2.10 level. Today the stock trades near $3.60.

Unfortunately, in the same article, we mentioned ArQule Inc. which was trading around $2.90 a share before reporting negative Phase III data. That caused the stock to sell off to the $2.50 mark. Catalyst trades offer significant returns as well as potentially punishing losses for mishandled trades. Investors must be nimble and diligent.

Today we focus on three small cap firms that may offer good upside potential as catalyst trades.

ImmunoCellular Therapeutics

The company is currently conducting a Phase II trial of ICT-107, which is a study in patients with newly diagnosed glioblastoma.

ImmunoCellular anticipates reporting interim safety analysis data in the first quarter of 2013. Afterwards, the company expects the final safety and efficacy results late in the second half of 2013.

According to John. S. Yu, MD, ImmunoCellular's Interim Chief Executive Officer:

"We believe that ICT-107 represents the next generation of cancer immunotherapy by targeting both tumor cells and cancer stem cells with a dendritic cell-based vaccine. We deeply appreciate the oncology community's enthusiasm for the ICT-107 clinical program and their shared interest in exploring the therapeutic potential of this potentially breakthrough technology, as reflected in the pace of enrollment in the trial. I congratulate the ImmunoCellular clinical team for this successful milestone in efficiently and rapidly completing enrollment in this complex clinical trial."

Dr. John Boockvar, director of the Brain Tumor Research Group, associate professor of neurological surgery at Weill Cornell Medical College and a neurosurgeon at NewYork-Presbyterian Hospital/Weill Cornell Medical Center remarked: